NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
September 18 2023 - 8:00AM
NuCana plc (NASDAQ: NCNA) announced four presentations at the
upcoming AACR-NCI-EORTC International Conference on Molecular
Targets and Cancer Therapeutics 2023 being held October 11-15, 2023
in Boston, Massachusetts.
The details of NuCana’s presentations at the
meeting are as follows:
Abstract title: NUC-3373 in
combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and
bevacizumab for second-line treatment of patients with advanced
colorectal cancer (NuTide:302)Poster number:
B048Session: Poster Session BSession date
and time: Friday, October 13 from
12:30pm-4:00pmPresenting Author: Dr. Khurum
Khan
Abstract title: Phase II study
of NUC-3373, leucovorin, irinotecan (NUFIRI) + bevacizumab vs
FOLFIRI + bevacizumab for the second-line treatment of patients
with advanced/metastatic colorectal cancer
(NuTide:323)Poster number:
B049Session: Poster Session BDate and
time: Friday, October 13 from
12:30pm-4:00pmPresenting Author: Professor Richard
Wilson
Abstract title: Phase Ib/II
open label, multi-arm, parallel cohort dose finding and expansion
study of NUC-3373 in combination with pembrolizumab in patients
with advanced solid tumors or docetaxel in patients with lung
cancer (NuTide:303)Poster number:
C029Session: Poster Session C Session date
and time: Saturday, October 14 from
12:30pm-4:00pmPresenting Author: Professor Richard
Wilson
Abstract title: NUC-7738 in
combination with pembrolizumab in patients with metastatic
melanoma: Phase 2 results from the NuTide:701 studyPoster
number: C032Session: Poster Session
CSession date and time: Saturday, October 14 from
12:30pm-4:00pmPresenting Author: Professor Sarah
Blagden
About NuCanaNuCana is a
clinical-stage biopharmaceutical company focused on significantly
improving treatment outcomes for patients with cancer by applying
our ProTide technology to transform some of the most widely
prescribed chemotherapy agents, nucleoside analogs, into more
effective and safer medicines. While these conventional agents
remain part of the standard of care for the treatment of many solid
and hematological tumors, they have significant shortcomings that
limit their efficacy and they are often poorly tolerated. Utilizing
our proprietary technology, we are developing new medicines,
ProTides, designed to overcome the key limitations of nucleoside
analogs and generate much higher concentrations of anti-cancer
metabolites in cancer cells. NuCana’s pipeline includes NUC-3373
and NUC-7738. NUC-3373 is a new chemical entity derived from the
nucleoside analog 5-fluorouracil, a widely used chemotherapy agent.
NUC-3373 is currently being evaluated in three ongoing clinical
studies: a Phase 1b/2 study (NuTide:302) in combination with
leucovorin, irinotecan or oxaliplatin, and bevacizumab in patients
with metastatic colorectal cancer; a randomized Phase 2 study
(NuTide:323) in combination with leucovorin, irinotecan, and
bevacizumab for the second-line treatment of patients with advanced
colorectal cancer; and a Phase 1b/2 modular study (NuTide:303) of
NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for
patients with advanced solid tumors and in combination with
docetaxel for patients with lung cancer. NUC-7738 is a
transformation of 3’-deoxyadenosine, a novel anti-cancer nucleoside
analog. NUC-7738 is in the Phase 2 part of a Phase 1/2 study in
patients with advanced solid tumors which is evaluating NUC-7738 as
a monotherapy and in combination with pembrolizumab.
Forward-Looking Statements This
press release may contain “forward-looking” statements within the
meaning of the Private Securities Litigation Reform Act of 1995
that are based on the beliefs and assumptions and on information
currently available to management of NuCana plc (the “Company”).
All statements other than statements of historical fact contained
in this press release are forward-looking statements, including
statements concerning the Company’s planned and ongoing clinical
studies for the Company’s product candidates and the potential
advantages of those product candidates, including NUC-3373 and
NUC-7738; the initiation, enrollment, timing, progress, release of
data from and results of those planned and ongoing clinical
studies; the Company’s goals with respect to the development,
regulatory pathway and potential use, if approved, of each of its
product candidates; the utility of prior non-clinical and clinical
data in determining future clinical results; and the sufficiency of
the Company’s current cash, cash equivalents and marketable
securities to fund its planned operations into 2025. In some cases,
you can identify forward-looking statements by terminology such as
“may,” “will,” “should,” “expects,” “plans,” “anticipates,”
“believes,” “estimates,” “predicts,” “potential” or “continue” or
the negative of these terms or other comparable terminology.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the Company’s actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. These risks and
uncertainties include, but are not limited to, the risks and
uncertainties set forth in the “Risk Factors” section of the
Company’s Annual Report on Form 20-F for the year ended December
31, 2022 filed with the Securities and Exchange Commission (“SEC”)
on April 4, 2023, and subsequent reports that the Company files
with the SEC. Forward-looking statements represent the Company’s
beliefs and assumptions only as of the date of this press release.
Although the Company believes that the expectations reflected in
the forward-looking statements are reasonable, it cannot guarantee
future results, levels of activity, performance or achievements.
Except as required by law, the Company assumes no obligation to
publicly update any forward-looking statements for any reason after
the date of this press release to conform any of the
forward-looking statements to actual results or to changes in its
expectations.
For more information, please contact:
NuCana plcHugh S. GriffithChief Executive
Officer +44 131-357-1111 info@nucana.com
ICR WestwickeChris Brinzey+1
339-970-2843chris.brinzey@westwicke.com
NuCana (NASDAQ:NCNA)
Historical Stock Chart
From Apr 2024 to May 2024
NuCana (NASDAQ:NCNA)
Historical Stock Chart
From May 2023 to May 2024